BiotechTube
AccurKardia

AccurKardia

San Francisco, United States· Est.
accurkardia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

AccurKardia is a private, commercial-stage digital health company developing AI-powered software to unlock deeper insights from ECG data. The company has achieved its first regulatory milestone with the FDA 510(k) clearance of its AccurECG™ interpretation application, positioning it in the cardiovascular diagnostics and remote monitoring market. Its pipeline includes investigational products, AK-AVS™ and AK+ Guard™, aimed at extending ECG analysis to new disease areas, signaling a strategic shift towards establishing the ECG as a broad biomarker. The company is led by a team with blended expertise in cardiology, medical devices, data analytics, and healthcare operations.

Cardiovascular

Technology Platform

Proprietary AI/ML engine designed to analyze standard 12-lead ECG data to extract visible and hidden signals, transforming the ECG into a broad diagnostic and predictive biomarker.

Funding History

1
Total raised:$1.2M
Seed$1.2M

Opportunities

The primary opportunity is to expand the clinical utility of the ubiquitous ECG into a multi-purpose biomarker for early detection and management of conditions like structural heart disease or heart failure, potentially disrupting more expensive diagnostic pathways.
The growth of remote patient monitoring and decentralized trials also offers a scalable market for a software-based diagnostic derived from simple ECG data.

Risk Factors

Key risks include the failure to clinically validate and gain regulatory clearance for novel AI-ECG applications, intense competition in the AI-cardiology space from both startups and large medtech firms, and the challenge of securing adequate insurance reimbursement for new AI-based diagnostic software.

Competitive Landscape

AccurKardia competes in the growing AI-ECG market against large medical device companies (e.g., GE Healthcare, Philips) with integrated ECG/AI solutions and specialized digital health rivals (e.g., iRhythm, AliveCor) focused on arrhythmia detection. Differentiation hinges on proving the superior clinical utility of its AI for novel, non-arrhythmia indications.

More companies in Diagnostics & Precision Medicine →More companies in United States →